Zenith Capital Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZHCLF research report →
Price Chart
About the company
Zenith Capital Corp. , a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer.
- CEO
- Donald J. McCaffrey
- IPO
- 2021
- Employees
- 50,477
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on ZHCLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.35M
- P/E
- -3.82
- PEG
- 0.80
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -10.06
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-3,199,000
- Net Income
- $-7,937,000-8.0%
- EPS
- $-0.05-3.5%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.30
- 52W Low
- $0.00
- 50D MA
- $0.07
- 200D MA
- $0.08
- Beta
- 687.84
- RSI (14)
- 61
- Avg Volume
- 10.37K
No earnings-call transcripts are available for ZHCLF yet.
- Free Float
- 98.0%
- Shares Outstanding
- 159.73M
- Float Shares
- 156.57M
Our ZHCLF coverage
Recent articles, reports, and earnings notes.
No research on ZHCLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZHCLF report →